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Brucellosis is a common, worldwide zoonosis. Clinical pres-
entation is protean and often goes unrecognized. Hepatic bru-
celloma is a rare local complication of chronic brucellosis. We 
report a case in which magnetic resonance imaging and pos-
itron emission tomography imaging prompted suspicion of a 
hepatic malignancy. Diagnosis was ultimately made by serology 
and polymerase chain reaction of resected liver tissue.
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CASE DESCRIPTION
A 56-year-old man without relevant medical history reported 
an episode of malaise, weakness, night sweats, and unintended 
weight loss followed by right upper quadrant abdominal pain 
worsened by inspiration. Laboratory testing (Table 1) revealed 
mild anemia, an elevated C-reactive protein of 55 mg/L, slightly 
elevated alkaline phosphatase, and negative tumor markers. 
Abdominal ultrasound and computed tomography (CT) iden-
tified an ill-defined mass of 9x5.5x6cm in the periphery of liver 
segments V/VI/VIII with one subcapsular, peripheral coarse 
calcification and inhomogeneous contrast enhancement in CT. 
As a fibrolamellar hepatocellular carcinoma was suspected, a 
positron emission tomography (PET–CT) was added for staging 
(Figure 1), which revealed high focal fluorodeoxyglucose (FDG) 
uptake of the hepatic mass without other lesions. A liver biopsy 
showed no malignancy, but periportal and portal fibrosis.
Further workup included magnetic resonance imaging 
(MRI) with hepatobiliary contrast agent (Gd-EOB-DTPA), 
which confirmed an ill-defined mass in liver segments V/VI/
VIII. Adjacent to the calcification, an ill-defined area with T2 
fat-sat hyperintense signal and arterial hyperenhancement was 
present. In the center of this area, portal-venous and hepato-
biliary contrast enhancement was decreased, representing the 
area of chronic inflammation. A  fluid collection resembling 
a hepatic abscess was not seen. A  second biopsy confirmed 
chronic portal and lobular inflammation with non-necrotiz-
ing microgranulomas, respectively (Figure  2). Histology 
triggered serologic testing for Bartonella spp., Brucella spp., 
and Coxiella burnetii. Agglutination test for brucellosis was 
reactive, and enzyme-linked immunosorbent assay (ELISA) 
confirmed elevated titers of Brucella IgG and IgA. However, 
Brucella spp.–specific polymerase chain reaction (PCR) of 
paraffin-embedded liver tissue tested negative. Serology for 
Coxiella burnetii and B.  henselae tested negative. Serological, 
radiological, and histological findings together with the risk 
factor, consumption of unpasteurized dairy products, resulted 
in the diagnosis of hepatic brucelloma. Treatment with doxy-
cycline 100  mg bis in die  (BID) and rifampin 300  mg ter in 
die (TID) was initiated. After initial improvement, abdominal 
pain and persistent elevation of inflammatory markers reoc-
curred. Abdominal MRI 5  months after treatment initiation 
revealed a new septated, subcapsular hepatic fluid collection 
suspicious of an abscess, prompting diagnostic and therapeutic 
puncture. Histopathology showed persistence of chronic gran-
ulomatous hepatitis. Brucella spp.–specific  PCR and culture 
were negative. At this time, trimethoprim/sulfamethoxazole 
160/800  mg BID was added to the antibiotic therapy. Due to 
subsequent clinical and laboratory improvement (C-reactive 
protein 10  mg/L, erythrocyte sedimentation rate 16  mm/h), 
antibiotics were stopped after 13  months of treatment. After 
12 weeks, a clinically, laboratory-, and imaging-verified relapse 
occurred. Doxycycline and rifampin were resumed, and the 
decision for surgical removal was taken. Perioperatively, gen-
tamicin was added to reduce bacterial load and discontinued 1 
week after partial hemihepatectomy. The postoperative course 
was uncomplicated, with rapid clinical and laboratory improve-
ment. Brucella spp.–specific PCR of the resected liver tissue was 
positive; culture remained negative. A follow up CT 3 months 
postoperation confirmed complete resection, and antibiotic 
therapy was stopped.
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DISCUSSION
Brucellosis is a frequent zoonosis caused by gram-negative fac-
ultative intracellular coccobacilli Brucella spp. Humans consti-
tute secondary hosts. Transmission results either from ingestion 
of unpasteurized dairy products or direct contact with infected 
animals. After an incubation period of 2 to 4 weeks, an unspe-
cific syndrome of fever, weight loss, malaise, myalgia, and arth-
ralgia presents [1]. Subclinical presentations are possible. No 
or insufficient treatment can lead to chronic brucellosis [1], of 
which hepatic brucelloma is an infrequent complication, with a 
reported incidence of 1.7% [2]. Symptoms of hepatic brucelloma 
are unspecific, including fever, chills, sweating, weakness, and 
upper abdominal pain. Laboratory tests frequently show signs of 
inflammation and occasionally elevations of gamma-glutamyl 
transpeptidase and alkaline phosphatase [2]. Serological tests, 
mostly agglutination assays, can be used for diagnosis. Cultural 
approaches are characterized by a low sensitivity (29.4%) [3], 
whereas PCR of biopsy samples is reported to be highly sensi-
tive (97.1%) [3]. Here, Brucella spp. PCR of percutaneous liver 
biopsies was negative, likely reflecting reduced sensitivity with 
the use of paraffin-embedded tissue and prior antibiotic ther-
apy. Brucella spp. PCR was only positive in operatively obtained 
samples.
Hepatic brucelloma presents as a hypodense lesion with peri-
focal calcium deposits and contrast enhancement on CT scans [4]. 
In the only published case describing PET-CT findings, high 
focal FDG uptake was reported [1]. Liver biopsies frequently 
display granulomatous, portal, and peripheral inflammation 
[5, 6].
Treatment recommendations for hepatic brucelloma are 
scarce. In a recent review, combination therapy with doxycyc-
line and rifampin was most often used, with a wide variability 
of treatment duration [1]. Occasionally, puncture or surgical 
resection was necessary for cure [7]. A decay in antibody titers 
during treatment is described, but no cutoff corresponding to 
treatment success has been established [8].
Table 1. Laboratory Results
Parameter Measurement [Reference Range]
Hemoglobin 125 g/L [134–170 g/L]
White blood count 9.07 G/L [3.0–9.6 G/L]
Platelets 270 G/L [143–400 G/L]
AST 21 U/L [<50 U/L]
ALT 21 U/L [<50 U/L]
gGT 58 U/L [<60 U/L]
AP 146 U/L [40–129 U/L]
Bilirubine 5 µmol/L [<21 µmol/L]
CRP 55 mg/L [<5 mg/L]
AFP 3.1 µg/L [<13.1 µg/L]
CA 19-9 7.9 kU/L [<37 kU/L]
CEA <1.0 µg/L [<5.0 µg/L]
Brucella agglutination assay Positive [negative] (11/15)
Positive [negative] (01/16)
Positive [negative] (02/16)
Brucella IgMa <5 U/L [<15 U/L] (11/15)
<5 U/L [<15 U/L] (01/16)
5.54 U/L [<15 U/L] (02/16)
Brucella IgGb 207.8 U/L [<20 U/L] (11/15)
163.0 U/L [<20 U/L] (01/16)
127.6 U/L [<20 U/L] (02/16)
Brucella IgAc >100 U/L [<10 U/L] (11/15)
89.7 U/L [<10 U/L] (01/16)
>100 U/L [<10 U/L] (02/16)
Brucella spp.–speficic PCR (liver biopsy) Negative [negative] (11/15)
Negative [negative] (07/16)
Positive [negative] (05/17)
Laboratory results at time of presentation (11/15), if other not specified.
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AP, alkaline phos-
phatase; AST, aspartate aminotransferase; CA 19-9, carbohydrate antigen 19-9; CEA, 
carcinoembryonic antigen; CRP, C-reative protein; gGT, gamma-glutamyl transpeptidase; 
PCR, polymerase chain reaction.
aVirion/serion SERION enzyme-linked immunosorbent assay (ELISA) classic Brucella IgM.
bVirion/serion SERION ELISA classic Brucella IgG.
cVirion/serion SERION ELISA classic Brucella IgA.
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Figure 1. Computed tomography (CT), positron emission tomography (PET)–CT, 
and magnetic resonance imaging (MRI) of the liver mass. A, Contrast-enhanced CT 
at initial diagnosis (08/15) with a coarse calcification and adjacent hyperenhance-
ment of the liver parenchyma in segments V/VI/VIII. B, FDG-PET-CT (09/15) shows 
corresponding FDG uptake of the hepatic lesion (SUVmax, standardized uptake 
value, 16.8). C, Contrast-enhanced MRI (10/15) with a T2-weighted fat-saturated 
image (C.1), contrast-enhanced images in the portal-venous (C.2), and hepatobil-
iary phase (C.3) showing the hypointense calcification (arrow). The adjacent area 
is hyperintense on T2 with increased contrast enhancement in the portal-venous 
phase and markedly decreased contrast enhancement in the hepatobiliary phase. 
D, Follow-up MRI (04/16) with contrast-enhanced image showing a subcapsular, 
septated hepatic abscess.
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CONCLUSIONS
Even advanced, noninvasive imaging methods cannot distin-
guish between hepatic malignancy and brucelloma. The optimal 
treatment for hepatic brucelloma is unknown, but prolonged 
antibiotic treatment combined with surgery can be necessary.
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Figure 2. Liver biopsy (11/15) showing portal and peripheral inflammation and a 
microgranuloma. aPortal inflammation. bPeripheral inflammation. cMagnification of 
a microgranuloma.
